BridgeBio starts dosing in phase 1/2 trial of BBP-398, Opdiv

BridgeBio Pharma (BBIO) said the first patient with non-small cell lung cancer ((NSCLC)) was dosed in a phase 1/2 trial of BBP-398 with Bristol Myers Squibb's (BMY) Opdivo (nivolumab)...

Related Keywords

China , Eli Wallace , Bristol Myers Squibb , Bristol Myers , Diverse Team Of Multi , Amgen , Medicine Research Laboratory , Modern Medicine Research Laboratory , Diverse Team , Multi Ethnic Young Scientists Passes Samples , Advanced Lab , High Tech Equipment , Microbiology Researchers Design , Develop Drugs , Bio Pharma ,